Angiotensin I-converting enzyme: A pathogenetic role in diabetic renal damage?

Current Diabetes Reviews

Volumn 3, Issue 1, 2007, Pages 41-52

  Lely, A Titia ^a   Luik, Peter T ^a   Navis, Gerjan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ACE; ACE genotype; Diabetes; RAAS

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; RENIN;

DATA ANALYSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC REGULATION; GENOTYPE; HEREDITY; HORMONE SENSITIVITY; HUMAN; KIDNEY INJURY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR SENSITIVITY; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK MANAGEMENT;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GENOTYPE; HUMANS; MODELS, BIOLOGICAL; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM;

EID: 34247127724     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339907779802049     Document Type: Review

References (104)

1. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining Incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994; 330: 15-18.
2. Hovind P, Tarnow L, Rossing K, et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes, diabetes care 2003; 26: 1258-1264.
3. Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 1983; 23: 647-655.
4. Yip JW, Jones SL, Wiseman MJ, Hill C, Viberti G. Glomerular hyperfiltration in the prediction of nephropathy in IDDM: a 10-year follow-up study. Diabetes 1996; 45: 1729-1733.
5. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930.
6. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
7. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
8. Lewis EJ, Hunsicker LG, Clarke WR, et al. The Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
9. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The irbesartan in patients with type: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
10. Winocour PH, Catalano C, Thomas TH, Wilkinson R, Alberti KG. Increased red cell sodium lithium countertransport activity, total exchangeable sodium, and hormonal control of sodium balance in normoalbuminuric type 1 diabetes. Diabet Med 1993; 10: 825-832.
11. de Azevedo MJ, Ramos OL, Gross JL. Renin-aldosterone axis in normoalbuminuric insulin-dependent diabetes mellitus patients with glomerular hyperfiltration. Diabetes Res Clin Pract 1995; 27: 205-210.
12. Hollenberg NK, Stevanovic R, Agarwal A, et al. Plasma aldosterone concentration in the patient with diabetes mellitus. Kidney Int 2004; 65: 1435-1439.
13. de Chatel R, Weidmann P, Flammer J, et al. Sodium, renin, aldosterone, catechola-mines, and blood pressure in diabetes mellitus. Kidney Int 1977; 12: 412-421.
14. Ferriss JB, O'Hare JA, Kelleher CC, et al. Diabetic control and the renin-angiotensin system, catecholamines, and blood pressure. Hypertension 1985; 7: II58-II63.
15. Lieberman J, Sastre A. Serum angiotensin-converting enzyme: elevations in diabetes mellitus. Ann Intern Med 1980; 93: 825-826.
16. van Dyk DJ, Erman A, Erman T, Chen-Gal B, Sulkes J, Boner G. Increased serum angiotensin converting enzyme activity in type I insulin-dependent diabetes mellitus: its relation to metabolic control and diabetic complications. Eur J Clin Invest 1994; 24: 463-467.
17. Feldt-Rasmussen B, Mathiesen ER, Deckert T, et al. Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 610-617.
18. Hoogenberg K, Sluiter WJ, Navis G, et al. Exogenous norepinephrine induces an enhanced microproteinuric response in microalbuminuric insulin-dependent diabetes mellitus. J Am Soc Nephrol 1998; 9: 643-654.
19. Anderson S. Role of local and systemic angiotensin in diabetic renal disease. Kidney Int Suppl 1997; 63: S107-S110.
20. O'Hare JA, Ferriss JB, Brady D, Twomey B, O'Sullivan DJ. Exchangeable sodium and renin in hypertensive diabetic patients with and without nephropathy. Hypertension 1985; 7: II43-II48.
21. Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechani-stic and endpoint data. Am J Cardiol 2001; 88: 1-20.
22. Lavoie JL, Sigmund CD. Minireview: overview of the renin-angiotensin system - an endocrine and paracrine system. Endocrinology 2003; 144: 2179-2183.
23. Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003; 24: 261-271.
24. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35: 1270-1277.
25. Vogt L, Kocks MJ, Laverman GD, Navis G. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance? Minerva Med 2004; 95: 395-409.
26. Kocks MJ, Gschwend S, de Zeeuw D, Navis G, Buikema H. Low sodium modifies the vascular effects of angiotensin-converting enzyme inhibitor therapy in healthy rats. J Pharmacol Exp Ther 2004; 310: 1183-1189.
27. Bos H, Laverman GD, Henning RH, et al. Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nep-hrotic rats. J Renin Angiotensin Aldosterone Syst 2003; 4: 106-112.
28. Largo R, Gomez-Garre D, Soto K, et al. Angiotensin-converting enzyme is upre-gulated in the proximal tubules of rats with intense proteinuria. J Am Soc Nephrol 1999; 33: 732-739.
29. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
30. Fujisawa T. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 1998; 41: 47-53.
31. Ha SK, Seo JK. Insertion/deletion polymorphism in ACE gene as a predictor for progression of diabetic nephropathy. Kidney Int Suppl 1997; 60: S28-S3.
32. Hadjadj S. Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study. J Am Soc Nephrol 2001; 12: 541-549.
33. Penno G, Chaturvedi N, Talmud PJ, et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 1998; 47: 1507-1511.
34. Jacobsen P, Rossing K, Rossing P, et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 1998; 53: 1002-1006.
35. Perna A, Ruggenenti P, Testa A, et al. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathiesl. Kidney Int 2000; 57: 274-281.
36. Parving HH, Jacobsen P, Tarnow L, et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ 1996; 313: 591-594.
37. Ng DP, Tai BC, Koh D, Tan KW, Chia KS. Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia 2005; 48: 1008-1016.
38. Kunz R, Bork JP, Fritsche L, Ringel J, Sharma AM. Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: A methodologic appraisal and systematic review. J Am Soc Nephrol 1998; 9: 1653-1663.
39. Rook M, Lely AT, Kramer AB, van GH, Navis G. Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage. Nephrol Dial Transplant 2005; 20: 59-64.
40. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-890.
41. Huang X, Chen W, Truong L, Lan H. Chymase is upregulated in diabetic nephropathy: Implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003; 14: 1738-1747.
42. Danser AH, Koning MM, Admiraal PJ, et al. Production of angiotensins I and II at tissue sites in intact pigs. Am J Physiol Heart Circ Physiol 1992; 263: H429-H437.
43. Cushman DW, Cheung HS. Concentrations of angiotensin-converting enzyme in tissues of the rat. Biochim Biophys Acta 1971; 250: 261-265.
44. Chai SY, Perich R, Jackson B, Mendelsohn FA, Johnston CI. Acute and chronic effects of angiotensin-converting enzyme inhibitors on tissue angiotensin-converting enzyme. Clin Exp Pharmacol Physiol 1992; 19: 7-12.
45. Boddi M, Poggesi L, Coppo M, et al. Human vascular renin-angiotensin system and its functional changes an relation to different sodium intakes. Hypertension 1998; 31: 836-842.
46. Johanning GL, Johnston KE, Tamura T, Goldenberg RL. Ethnic differences in angiotensin converting enzyme gene polymorphism. J Hypertens 1995; 13: 710-711.
47. Barley J, Blackwood A, Carter ND, et al. Angiotensin converting enzyme insertion/deletion polymorphism: association with ethnic origin. J Hypertens 1994; 12: 955-957.
48. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion poly-morphism. Circulation 1995; 92: 1387-1388.
49. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J 1993; 290: 33-40.
50. Mizuiri S, Hemmi H, Kumanomidou H, et al. Angiotensin-converting enzyme (ACE) I/D genotype and renal ACE gene expression. Kidney Int 2001; 60: 1124-1130.
51. Muller DN, Bohlender J, Hilgers KF, et al. Vascular angiotensin-converting enzyme expression regulates local angiotensin II. Hypertension 1997; 29: 98-104.
52. Ustundag B, Canatan H, Cinkilinc N, Halifeoglu L, Bahcecioglu IH. Angiotensin converting enzyme (ACE) activity levels an insulin-independent diabetes mellitus and effect of ACE levels on diabetic patients with nephropathy. Cell Biochem Funct 2000; 18: 23-28.
53. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-828.
54. Oudit GY, Herzenberg AM, Kassiri Z. et al. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 2006; 168: 1808-1820.
55. Lely AT, Hamming I, Van Goor H, Navis GJ. Renal ACE2 expression in human kidney disease. J Pathol 2004; 204: 587-593.
56. Hamming I, Timens W, Bulthuis M, Lely A, Navis G, Van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203: 631-637.
57. Yagil Y, Yagil C. Hypothesis: ACE2 modulates blood pressure in the mammalian organism. Hypertension 2003; 41: 871-873.
58. Christlieb AR, Kaldany A, D'Elia JA, Williams GH. Aldosterone responsiveness in patients with diabetes mellitus. Diabetes 1978; 27: 732-737.
59. Cronin CC, Barry D, Crowley B, Ferriss JB. Reduced plasma aldosterone concentrations in randomly selected patients with insulin-dependent diabetes mellitus. Diabet Med 1995; 12: 809-815.
60. Beretta-Piccoli C, Elshater-Zanetti F, Shaw S, Cusi D, Weidmann P. Acute sodium loading in patients with uncomplicated diabetes mellitus: renal and hormonal effects. Clin Sci (Lond) 1994; 86: 383-390.
61. Luik PT, Kerstens MN, Hoogenberg K, Navis GJ, Dullaart RP. Low plasma aldosterone despite normal plasma renin activity in uncomplicated type 1 diabetes mellitus: effects of RAAS stimulation. Eur J Clin Invest 2003; 33: 787-793.
62. Perez GO, Lespier L, Jacobi J, et al. Hyporeninemia and hypo-aldosteronism in diabetes mellitus. Arch Intern Med 1977; 137: 852-855.
63. Beretta-Piccoli C, Weidmann P, Fraser R. Responsiveness of plasma 18-hydroxycorticosterone and aldosterone to angiotensin II or corticotropin in nonazotemic diabetes mellitus. Diabetes 1983; 32:1-5.
64. Fioretto P, Sambataro M, Cipollina MG, et al. Impaired response to angiotensin II in type 1 (insulin-dependent) diabetes mellitus. Role of prostaglandins and sodium-lithium counter-transport activity. Diabetologia 1991; 34: 595-603.
65. Trevisan R, Bruttomesso D, Vedovato M, et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes 1998; 47: 1347-1353.
66. Christlieb AR, Janka HU, Kraus B, et al. Vascular reactivity to angio-tensin II and to norepinephrine in diabetic subjects. Diabetes 1976; 25: 268-274.
67. Eadington DW, Swainson CP, Frier BM, Semple PF. Renal responses to angiotensin II infusion an early type 1 (insulin-dependent) diabetes. Diabet Med 1991; 8: 524-531.
68. Bjorck S, Aurell M, Bresater LE, Herlitz H, Welin L, Wikstrand J. Renal sensitivity to angiotensin II in type 1 diabetes. Scand J Urol Nephrol 1990; 24: 267-273.
69. MaassenVanDenBrink A, de Vries R, Saxena PR, Schalekamp MA, Danser AH. Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase. Cardiovasc Res 1999; 44: 407-415.
70. Navar LG, Lewis L, Hymel A, Braam B, Mitchell KD. Tubular fluid concentrations and kidney contents of angiotensins I and II in anesthetized rats. J Am Soc Nephrol 1994; 5: 1153-1158.
71. Seikaly MG, Arant BS, Jr., Seney FD, Jr. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 1990; 86: 1352-1357.
72. Bjorck S. The renin angiotensin system in diabetes mellitus. A physiological and therapeutic study. Scand J Urol Nephrol Suppl 1990; 126: 1-51.
73. Price DA, Porter LE, Gordon M, et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999; 10: 2382-2391.
74. Gordon MS, Price DA, Hollenberg NK. Blunted suppression of plasma renin activity in diabetes. J Renin Angiotensin Aldosterone Syst 2000; 1: 252-256.
75. Price DA, De'Oliveira JM, Fisher ND, Williams GH, Hollenberg NK. The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus. Am J Hypertens 1999; 12: 348-355.
76. Hollenberg NK, Price DA, Fisher ND, et al. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 2003; 63: 172-178.
77. Lansang MC, Price DA, Laffel LM, et al. Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus. Kidney Int 2001; 59: 1432-1438.
78. Mizuiri S, Yoshikawa H, Tanegashima M, et al. Renal ACE immunohistochemical localization in NIDDM patients with nephropathy. Am J Kidney Dis 1998; 31: 301-307.
79. Mezzano S, Droguett A, Burgos ME, et al. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int 2003; Suppl: S64-S70.
80. Obata J, Nakamura T, Takano H, et al.: Increased gene expression of components of the renin-angiotensin system in glomeruli of genetically hypertensive rats. J Hypertens 2000; 18: 1247-1255.
81. Huang W, Gallois Y, Bouby N, et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci USA 2001; 98: 13330-13334.
82. Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000; 36: 449-467.
83. Tikellis C. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003; 41: 392.
84. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice. A renoprotective combination? Hypertension 2004; 43: 1120-1125.
85. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 2006; 17: 3067-3075.
86. Luik PT, Hoogenberg K, Kerstens MN, et al. The influence of the ACE (I/D) polymorphism on systemic and renal vascular responses to angiotensins in normotensive, normoalbuminuric Type 1 diabetes mellitus. Diabetologia 2003; 46: 1131-1139.
87. van der Kleij FG, de Jong PE, Henning RH, de Zeeuw D, Navis G. Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake. J Am Soc Nephrol 2002; 13: 1025-1033.
88. Staessen JA, Wang J, Ginocchio G, et al. The deletion/insertion polymorphism of the ACE gene and cardiovascular-renal risk. Hypertension 1997; 30: 16.
89. Jacobsen PK, Tarnow L, Parving HH. Time to consider ACE insertion/ deletion genotypes and individual renoprotective treatment in diabetic nephropathy? Kidney Int 2006; 69: 1293-1295.
90. Tanaka C, Kamide K, Takiuchi S. et al. An alternative fast and convenient genotyping method for the screening of angiotensin converting enzyme gene poly-morphisms. Hypertens Res 2003; 26: 301-306.
91. Ueda S, Meredith PA, Morton JJ, Connell JMC, Elliott HL. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (Enalaprilat) in humans, circulation 1998; 98: 2148-2153.
92. Danser AH, Deinum J, Osterop AP, Admiraal PJ, Schalekamp MA. Angiotensin I to angiotensin II conversion in the human forearm and leg. Effect of the angiotensin converting enzyme gene insertion/deletion polymorphism. J Hypertens 1999; 17: 1867-1872.
93. van Dijk MA, Kroon I, Kamper AM, Boomsma F, Danser AH, Chang PC. The angiotensin-converting enzyme gene polymorphism and responses to angiotensins and bradykinin in the human forearm. J Cardiovasc Pharmacol 2000; 35: 484-490.
94. Gaudio G, Guasti L, Schizzarotto A, et al. Changes in plasma lipids during renin-angiotensin system blockade by combination therapy (enalapril plus valsartan) in patients with diebetes and hypertension. J Cardiovasc Pharmacol 2005; 45: 362-366.
95. Weekers L, Bouhanick B, Hadjadj S, et al. Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients. Diabetes 2005; 54: 2961-2967.
96. Marre M. Renal changes on hyperglycemia and angiotensin-converting enzyme in type 1 diabetes. Hypertension 1999; 33: 775-780.
97. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13: 1682-1685.
98. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36: 272-279.
99. van der Kleij FG, Schmidt A, Navis GJ, et al. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. Kidney Int Suppl 1997; 63: S23-S26.
100. Gaudio G, Guasti L, Schizzarotto A, et al. Changes in plasma lipids during renin-angiotensin system blockade by combination therapy (enalapril plus valsartan) in patients with diabetes and hypertension. J Cardiovasc Pharmacol 2005; 45: 362-366.
101. Lely AT, Visser F, Kocks MJA, Zuurman MW, Navis G. Selective blunting of blood pressure response to ACE-inhibition by high sodium in ACE DD genotype in healthy men. (abstract) J Am Soc Nephrol 2005; 16: 182A.
102. Parving HH, de Zeeuw D, Cooper ME, et al. Influence of angiotensin converting enzyme insertion deletion polymorphism on renal outcomes and death in relation to losartan treatment in patients with type 2 diabetes and nephropathy. (abstract) J Am Soc Nephrol 2006; 17: 101A.
103. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47: 1936-1939.
104. Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone. Horm Metab Res 2005; 37 Suppl 1: 4-8.